Cross-Sector entity
Rosen Law Firm is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. corporate-law accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 10 original sources on average.
3 verified stories tracked
Last mentioned: Feb 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Rosen Law Firm is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. corporate-law accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 10 original sources on average. We currently track 3 Cross-Sector stories that mention Corcept Therapeutics Incorporated, all published on February 24, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Corcept Therapeutics Incorporated. Shared-story counts are live from our verified record — not editorial picks.
Lawsuit Announced
Rosen Law Firm announces the filing of the securities fraud class action.
Appellate Loss
Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.
Teva Legal Victory
Teva Pharmaceutical Industries wins an appeals court ruling over generic versions of Corcept's Korlym.
Class Period Ends
Conclusion of the period following corrective disclosures or market events.
Class Period Begins
Start of the period during which alleged misleading statements were made.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.
Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.
Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud between October 2024 and December 2025. The Rosen Law Firm is leading the litigation, which centers on claims that the company misled investors regarding its business operations and regulatory compliance. This legal challenge marks a critical period of scrutiny for the pharmaceutical firm's corporate governance and public disclosure practices.
Source: Finger Lakes Times · Pr Newswire
